Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Submitted by
admin
on July 18, 2018 - 10:00am
Source:
CP Wire
News Tags:
Takeda
Ovid Therapeutics
TAK-935/OV935
Headline:
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
snippet:
TAK-935/OV935 is a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase
TAK-935/OV935 may potentially treat rare epilepsies by inhibiting CH24H to decrease 24HC levels
In previous Ph I trial TAK-935/OV935 reduced 24HC levels between 47 and 63 percent
Do Not Allow Advertisers to Use My Personal information
